Operating Company Healthcare

Symeres

Nijmegen, Gelderland, Netherlands

Transatlantic contract research, development and manufacturing organization (CRO/CDMO) supporting pharmaceutical and biotechnology companies across the drug development lifecycle, from early discovery through IND-enabling work and GMP manufacturing, including medicinal chemistry, ADME-Tox, bioanalysis, solid-state chemistry, process development, CMC, and regulatory support.

Focus Areas
Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), Small-molecule drug discovery
Website
symeres.com

Tracked deals

3

3 tracked deals across 2022-2023.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

3 addon

Symeres Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Symeres. 2 2022 1 2023

Supporting Data

Recent Transactions

  • Symeres Acquires Oncolines
    January 10, 2023
    Buyer
    Symeres, Keensight Capital
    Target
    Oncolines
    Seller
    NTRC Holding
    Industry
    Healthcare Services
    Location
    North Brabant, Netherlands
    Type
    Addon

    Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.

  • Symeres Acquires Exemplify BioPharma
    October 25, 2022
    Buyer
    Symeres, Keensight Capital
    Target
    Exemplify BioPharma
    Industry
    Pharmaceuticals
    Location
    New Jersey, United States
    Type
    Addon

    Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.

  • Symeres Acquires Organix Inc.
    April 26, 2022
    Buyer
    Symeres, Keensight Capital
    Target
    Organix Inc.
    Seller
    Dr. Anu Mahadevan and Dr. Paul Blundell (Organix management / owners)
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Addon

    Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 1 tracked deal by Symeres. Healthcare Services Buyers & Acquisitions 1 tracked deal by Symeres. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Symeres. Acquisitions in Massachusetts 1 tracked deal by Symeres. Acquisitions in New Jersey 1 tracked deal by Symeres.

Selling a company? Get in front of buyers like Symeres

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →